Fenofibrate impairs liver function and structure more pronounced in old than young rats |
| |
| Institution: | 1. Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI, United States;2. Department of Public Health, Robbins College of Health and Human Sciences, Baylor University, Waco, TX, United States;1. Institute of Management and Department EMbeDS, Management and Health Laboratory, Scuola Superiore Sant’Anna, Pisa, Italy;2. Social and Political Sciences Department, Università Bocconi, Milan, Italy;3. CERGAS-SDA, Università Bocconi, Milan, Italy;4. Geriatric Institute “Camillo Golgi”, ASP Golgi Redaelli, Abbiategrasso, Milan, Italy;5. Golgi Cenci Foundation, Abbiategrasso, Milan, Italy;1. Division of Neurology, Department of Medicine, The Ottawa Hospital, 1053 Carling Avenue, Ottawa, ON, K1Y 4E9, Canada;2. Center for Population Health IT, Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, 624 N Broadway, Baltimore, MD, 21205, United States;3. Center for Transformative Geriatric Research, Division of Geriatric Medicine and Gerontology, Johns Hopkins University School of Medicine, 200 Eastern Avenue, Baltimore, MD, 21224, United States;4. Division of Health Sciences and Informatics, Department of General Internal Medicine, Johns Hopkins University School of Medicine, 2024 East Monument St. S 1-200, Baltimore, MD, 21205, United States;1. Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Faculty of Medicine, Nursing and Health Sciences, Monash University, 553 St Kilda Road, Melbourne, Victoria, 3004 Australia;2. Department of Pharmacy Practice and Science, College of Pharmacy, Department of Family Medicine, Carver College of Medicine, The University of Iowa;3. Menzies Institute for Medical Research, University of Tasmania;4. Berman Center for Outcomes & Clinical Research, Minneapolis;5. Centre for Healthy Brain Ageing, University of New South Wales;1. Monterrey, NL, Mexico;2. Senior Fellow, Sealy Center on Aging; Director, WHO/PAHO Collaborating Center on Aging and Health, The University of Texas Medical Branch, United States |
| |
| Abstract: | IntroductionSince old animals are known to accumulate lipids in some organs, we compared effects of fenofibrate (FN) on systemic lipid metabolism, activity of liver marker enzymes and structure in young and old rats.Material and methodsYoung and old rats were fed chow supplemented with 0.1 % or 0.5 % FN. After 30 days, intraperitoneal glucose tolerance test (IPGTT) was performed, and blood and liver samples were collected.ResultsIn young rats, 0.1 % FN, but not 0.5 % FN, decreased serum Chol by 74 %, and did not affect TG levels at either doses. In old rats, 0.5 % FN, but not 0.1 % FN, decreased Chol and TG level by 56 % and 49 %, respectively. In young rats, 0.1 % and 0.5 % FN increased serum activity of ALP by 227 % and 260 %, respectively, and did not affect AST and ALT activities. In old rats, only 0.5 % FN increased serum ALP activity by 150 %, respectively. In old rats, neither dose of FN affected serum AST activity, and only 0.5 % FN increased serum ALT activity by 200 %. The histological examination of liver structure revealed that both doses of FN impaired lobular architecture, expansion of bile canaliculi, and degeneration of parenchymal cells with the presence of cells containing fat droplets; administration of FN increased area occupied by collagen fibers.ConclusionsAlthough 0.5 % FN decreased serum Chol concentration, it increased serum ALP activity and impaired liver structure in both in both age groups of rats. Thus, FN treatment should be under the control of liver function, especially in older patients. |
| |
| Keywords: | Aging Fenofibrate Rat serum Lipids Liver function and morphology |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
